Fundamental Analysis of ZyVersa Therapeutics Inc. - Growth / Value Index
ZVSA - Valuation Highlights
Valuation Analysis
Price to Book Ratio is 0.0000 indicating that it is undervalued.
Book Value in last 3 years is trending up
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -0.0005 | -4.89 | -316937.52 % | |
| Price to Book | 0.0001 | 0.0395 | -96.58 % | 0.0002 |
| Price to Sales | 87.78 | 0 | 0 % | |
| Enterprise Value to EBITDA Multiple | 1.10 | 30.06 | 18340709 % |
ZVSA - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Very Poor Score of 5.00
Piotroski F Score - Very Poor Value of 2.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Net Margin
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -13.17 | -0.809 | 100.00 % | -25.19 |
| Return On Asset | -10.42 | -0.405 | 100.00 % | -13.06 |
| Net Profit Margin | -18727506.38 | 0 | 0 % | 0 |
| Operating Profit Margin | -18182466.02 | 0 | 0 % | 0 |
| EBITDA Margin | -18182412.91 | 0 | 0 % | 0 |
Highlights
| Market Cap | 3407.97 K |
| Enterprise Value | -3125.61 M |
| Price/Book TTM | 0.0001 |
| Outstanding Share | 759486 |
| Float/ Outstanding Share | 108.43% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 2.00 |
| Altman Z Score | -6.55 |
| Sloan Ratio | -0.0038 |
| Peter Lynch Fair Value | 0 |
ZVSA - Growth Highlights
Growth Analysis
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Quarterly sales in last 5 Quarter is trending down
Annual sales in last 3 years is trending down
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 15600.00 | % | 100.00 % |
| Gross Profit | -18239.00 | 0 % | 301.50 % |
| EBITDA | -2836.46 M | 113.37 % | 159271 % |
| Net Profit | -2921.49 M | 19.39 % | 21092.32 % |
| EPS | -9572.73 | 99.97 % | NA |
ZVSA - Stability Highlights
Stability Analysis
Altman Z Score of -6.55 suggest high risk
Company is unable to generate enough free cash to support the business.
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0008 | -28.38 % | 0 |
| Cash Ratio | 0.308 | -57.30 % | |
| Quick Ratio | 0 | 0 % | 0.303 |
| Shareholders Equity | 50.08 | -40.45 % | |
| Debt to EBITDA | -0.097 | -59548347.24 % |
Historical Valuation Ratios of ZyVersa Therapeutics Inc.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of ZyVersa Therapeutics Inc.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of ZyVersa Therapeutics Inc.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of ZyVersa Therapeutics Inc.
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)